Reporting sexual function disorders caused by antipsychotic drugs: is there a role for the community pharmacy? C.A.W. RijckenJ.A.M. Dekens‐KonterH. Knegtering Commentary Pages: 169 - 172
Patients' opinions of CFC‐free inhaler changeover in primary care F. ArrisL. ThorburnD.J. McCaig Legacy Pages: 173 - 174
Pharmaceutical care needs of patients with angina E.M. McGovernC. MackayS.M. Bryson Legacy Pages: 175 - 176
Evaluation of the implementation of a local treatment guideline in secondary prevention post-myocardial infarction F. ReidB. FosslandS.A. Hudson Legacy Pages: 177 - 178
The incidence and reporting of adverse drug reactions in the Division of Psychiatry P. BrownL. Faloon Legacy Pages: 181 - 182
Identification of the pharmaceutical care issues of rheumatoid arthritis patients in secondary care R. O'HareA. MuirS.A. Hudson Legacy Pages: 183 - 184
Patients' evaluation of shape, size and colour of solid dosage forms A.B.A. OvergaardJ. Møller‐SonnergaardR. Hansen OriginalPaper Pages: 185 - 188
The pharmaceutical care of patients with hypertension: an examination of service models in primary care in the US J.J. McAnawS.A. HudsonA‐M. McGregor OriginalPaper Pages: 189 - 194
Nursing and residential care for the elderly in Northern Ireland: the contribution of the pharmacist Anna K. SchweizerCarmel M. Hughes OriginalPaper Pages: 195 - 199
Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus D.J. TouwJ.H. ProostM.M. van Weissenbruch OriginalPaper Pages: 200 - 204
